{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:25:55Z","timestamp":1772249155268,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11912-020-0883-2","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T18:02:37Z","timestamp":1581184957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Lymphadenectomy in Ovarian Cancer: Is It Still Justified?"],"prefix":"10.1007","volume":"22","author":[{"given":"Pierluigi","family":"Benedetti Panici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Fischetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Lecce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,8]]},"reference":[{"key":"883_CR1","unstructured":"J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, GLOBOCAN 2008 (Version 1.2), Cancer incidence and mortality worldwide, Lyon, France, International Agency for Research on Cancer, 2010 Available from"},{"issue":"2","key":"883_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000448942","volume":"62","author":"A Musella","year":"2017","unstructured":"Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, et al. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy. 2017;62(2):111\u201320. https:\/\/doi.org\/10.1159\/000448942 Epub 2016 Oct 29. Review.PMID: 27794568.","journal-title":"Chemotherapy"},{"key":"883_CR3","unstructured":"Cancer Statistics Center, American Cancer Society, cancerstatisticscenter.otg."},{"issue":"1","key":"883_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10\u201330.","journal-title":"CA Cancer J Clin"},{"key":"883_CR5","unstructured":"Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review, 1975\u20132001. Bethesda (MD): National Cancer Institute."},{"key":"883_CR6","unstructured":"American Cancer Society: ovarian cancer, Available at: www.cancer.org Last accessed: December 11, 2016."},{"issue":"8","key":"883_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1477-7819-8-106","volume":"30","author":"D Desteli","year":"2010","unstructured":"Desteli D, Gultekin M, Usubutin A, et al. Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: hacettepe experience and review of literature. World J Surg Oncol. 2010;30(8):106.","journal-title":"World J Surg Oncol"},{"key":"883_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1006\/gyno.1993.1263","volume":"51","author":"P Benedetti-Panici","year":"1993","unstructured":"Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 1993;51:150\u20134.","journal-title":"Gynecol Oncol"},{"key":"883_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1072-7515(03)00234-5","volume":"197","author":"P Morice","year":"2003","unstructured":"Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197:198\u2013205.","journal-title":"J Am Coll Surg"},{"issue":"8","key":"883_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ejso.2014.04.001","volume":"40","author":"A Pereira","year":"2014","unstructured":"Pereira A, P\u00e9rez-Medina T, Magrina JF, et al. Correlation between the extent of intraperitoneal disease and nodal metastasis in node-positive ovarian cancer patients. Eur J Surg Oncol. 2014;40(8):917\u201324.","journal-title":"Eur J Surg Oncol"},{"key":"883_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2407-8-367","volume":"8","author":"F Legge","year":"2008","unstructured":"Legge F, Petrillo M, Adamo V, et al. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer. 2008;8:367.","journal-title":"BMC Cancer"},{"issue":"2","key":"883_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ygyno.2013.08.022","volume":"131","author":"M Signorelli","year":"2013","unstructured":"Signorelli M, Guerra L, Pirovano C, et al. Detection of nodal metastases by 18F-FDG PET\/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol. 2013;131(2):395\u20139.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"883_CR13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1007\/s00259-008-0890-2","volume":"35","author":"K Kitajima","year":"2008","unstructured":"Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET\/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35(10):1912\u201320. https:\/\/doi.org\/10.1007\/s00259-008-0890-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"883_CR14","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.ejrad.2010.07.013","volume":"80","author":"P De Iaco","year":"2011","unstructured":"De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET\/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol. 2011;80(2):e98\u2013103. https:\/\/doi.org\/10.1016\/j.ejrad.2010.07.013 Epub 2010 Aug 4.","journal-title":"Eur J Radiol"},{"issue":"3","key":"883_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ygyno.2011.09.013","volume":"123","author":"M Kleppe","year":"2011","unstructured":"Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2011.09.013 Epub 2011 Oct 6. Review.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"883_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2017.07.139","volume":"147","author":"G Bogani","year":"2017","unstructured":"Bogani G, Tagliabue E, Ditto A, Signorelli M, Martinelli F, Casarin J, et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: a predictors- and nomogram-based analyses. Gynecol Oncol. 2017;147(1):61\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.139 Epub 2017 Aug 2.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"883_CR17","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/IGC.0000000000000787","volume":"26","author":"V Lago","year":"2016","unstructured":"Lago V, Minig L, Fotopoulou C. Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer: a comprehensive review. Int J Gynecol Cancer. 2016;26(8):1407\u201314. https:\/\/doi.org\/10.1097\/IGC.0000000000000787 Review.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"883_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ygyno.2011.05.001","volume":"122","author":"CA Powless","year":"2011","unstructured":"Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122(3):536\u201340. https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.001 Epub 2011 Jun 1.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"883_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/sj.bjc.6603323","volume":"95","author":"A Maggioni","year":"2006","unstructured":"\u2022 Maggioni A, Benedetti Panici P, Dell-Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95(6):699\u2013704 (A multicentric randomized trial evaluating the value of systematic lymphadenectomy in early EOC demonstrates no statistically significant difference in 5-year overall survival among the lymphadenectomy group and the control group.).","journal-title":"Br J Cancer"},{"issue":"1","key":"883_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/COC.0b013e318134ee6f","volume":"31","author":"DS Dizon","year":"2008","unstructured":"Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, et al. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol. 2008;31(1):39\u201342. https:\/\/doi.org\/10.1097\/COC.0b013e318134ee6f.","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 2","key":"883_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/ijgc-00009577-200311001-00002","volume":"13","author":"N Colombo","year":"2003","unstructured":"Colombo N, Pecorelli S. What have we learned from ICON1 and ACTION? Int J Gynecol Cancer. 2003;13(Suppl 2):140\u20133.","journal-title":"Int J Gynecol Cancer"},{"key":"883_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/jnci\/dji102","volume":"97","author":"PB Panici","year":"2005","unstructured":"\u2022 Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560\u20136 (One of the most important randomized study shows that retroperitoneal staging is correlated with a higher incidence of surgery-related morbidity, post-operative stay, and costs.).","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"883_CR23","doi-asserted-by":"publisher","first-page":"324.e1","DOI":"10.1016\/j.ajog.2019.05.005","volume":"221","author":"S Uccella","year":"2019","unstructured":"Uccella S, Nero C, Vizza E, Vargiu V, Corrado G, Bizzarri N, et al. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). Am J Obstet Gynecol. 2019;221(4):324.e1\u2013324.e10. https:\/\/doi.org\/10.1016\/j.ajog.2019.05.005 Epub 2019 May 10.","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 6","key":"883_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):24\u201332.","journal-title":"Ann Oncol"},{"key":"883_CR25","unstructured":"NCCN Clinical practice guidelines in oncology (NCCN Guidelines Version 2.2019 Panel Members Ovarian Cancer). http:\/\/www.nccn.org\/professionals\/physician_ gls\/f_guidelines.asp."},{"key":"883_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijsu.2018.02.006","volume":"52","author":"J Zhou","year":"2018","unstructured":"Zhou J, Zhang W, Zhang QG, He ZY, Sun JY, Chen QH, et al. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: a population-based study. Int J Surg. 2018;52:11\u20135.","journal-title":"Int J Surg"},{"key":"883_CR27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1525-1438.2007.00931.x","volume":"17","author":"P Harter","year":"2007","unstructured":"Harter P, Gnauert K, Hils R, Lehmann TG, Fisseler-Eckhoff A, Traut A, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238\u201344.","journal-title":"Int J Gynecol Cancer"},{"key":"883_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1006\/gyno.2001.6232","volume":"82","author":"SM Eisenkop","year":"2001","unstructured":"Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol. 2001;82:143\u20139.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"883_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ejso.2013.11.026","volume":"40","author":"A Ferrero","year":"2014","unstructured":"Ferrero A, Ditto A, Giorda G, et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur J Surg Oncol. 2014;40(7):891\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"883_CR30","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1200\/JCO.2009.25.3617","volume":"28","author":"A Du Bois","year":"2010","unstructured":"Du Bois A, Reuss A, Harter P, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"883_CR31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"\u2022\u2022 Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1808424(The last randomized trial shows that level one evidence has no survival benefit correlated to lymphadenectomy in complete debulky ovarian cancer.).","journal-title":"N Engl J Med"},{"issue":"6","key":"883_CR32","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1245\/s10434-016-5680-7","volume":"24","author":"V Di Donato","year":"2017","unstructured":"\u2022 Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, et al. Trends in mortality after primary cytoreductive surgery for ovarian cancer: a systematic review and metaregression of randomized clinical trials and observational studies. Ann Surg Oncol. 2017;24(6):1688\u201397. https:\/\/doi.org\/10.1245\/s10434-016-5680-7(This study analyzes all study present in literature and shows incidence and predictor of peri-operative mortality in the surgery treatment for advanced EOC.).","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"883_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ygyno.2015.03.043","volume":"137","author":"P Benedetti Panici","year":"2015","unstructured":"Benedetti Panici P, Di Donato V, Fischetti M, Casorelli A, Perniola G, Musella A, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 2015;137(3):406\u201311. https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.043 Epub 2015 Mar 28.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"883_CR34","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.7314\/APJCP.2015.16.9.3635","volume":"16","author":"ML Gasparri","year":"2015","unstructured":"Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, et al. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev. 2015;16(9):3635\u20138 Review.","journal-title":"Asian Pac J Cancer Prev"},{"key":"883_CR35","doi-asserted-by":"crossref","unstructured":"Benedetti Panici P, Perniola G, Angioli R, Zullo MA, Manci N et al. Basile S Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer 2007;17(6):1245\u20131251. Epub 2007 Apr 8.","DOI":"10.1111\/j.1525-1438.2007.00929.x"},{"key":"883_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2009.04.025","volume":"114","author":"S Fotiou","year":"2009","unstructured":"Fotiou S, Aliki T, Petros Z, et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol. 2009;114:178\u201382.","journal-title":"Gynecol Oncol"},{"key":"883_CR37","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1245\/ASO.2004.11.023","volume":"11","author":"C Uzan","year":"2004","unstructured":"Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol. 2004;11:658\u201364.","journal-title":"Ann Surg Oncol"},{"key":"883_CR38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ygyno.2006.10.020","volume":"104","author":"A Santillan","year":"2007","unstructured":"Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104:686\u201390.","journal-title":"Gynecol Oncol"},{"issue":"15_suppl","key":"883_CR39","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Du Bois","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"883_CR40","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"RL Coleman","year":"2018","unstructured":"Coleman RL, Enserro D, Spirtos N, Herzog TJ, Sabbatini P, Armstrong DK, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology\/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36(15_suppl):5501. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5501.","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0883-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-020-0883-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0883-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T03:14:09Z","timestamp":1612840449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-020-0883-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["883"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-0883-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,8]]},"assertion":[{"value":"8 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"22"}}